Defence Therapeutics Quote - DTC

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.60

Bid

0.55

Offer

0.60

Volume

8,500

0.60 Day's Range 0.60

0.48 52 Week Range 2.55

Previous Close

0.54

Open

0.60

Last Trade

500

0.6

Last Trade Time

Average Volume (3m)

24,657

Financial Volume

VWAP

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 Vancouver, BC, Canada, January 26th...

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS Vancouver, BC, Canada, November...

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER Vancouver, BC, Canada, October 13th...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.08	15.3846153846	0.52	0.67	0.49	42464	0.52998964	CS
4	0.06	11.1111111111	0.54	0.67	0.49	26709	0.52934105	CS
12	0.05	9.09090909091	0.55	0.67	0.49	24657	0.56546027	CS
26	-0.22	-26.8292682927	0.82	0.96	0.48	31379	0.66087181	CS
52	-1.64	-73.2142857143	2.24	2.55	0.48	29379	1.0547225	CS
156	-5	-89.2857142857	5.6	5.65	0.48	19451	2.07195672	CS
260	-1.15	-65.7142857143	1.75	8.15	0.48	18564	2.541621	CS

DTC - Frequently Asked Questions (FAQ)

What is the current Defence Therapeutics share price?

The current share price of Defence Therapeutics is $ 0.60

What is the 1 year trading range for Defence Therapeutics share price?

Defence Therapeutics has traded in the range of $ 0.48 to $ 2.55 during the past year

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CNTRCENTR Brands Corp	$ 0.15 (114.29%)	31.1k
BEEBee Vectoring Technologies International Inc	$ 0.01 (100.00%)	108.8k
AWRAurwest Resources Corporation	$ 0.01 (100.00%)	20k
WINCommon Stock	$ 0.015 (50.00%)	2.6k
RXMRockex Mining Corporation	$ 0.015 (50.00%)	1.73k
HROHero Innovation Group Inc	$ 0.005 (-66.67%)	100k
NXU.XNexco Resources Inc	$ 0.005 (-50.00%)	4k
PUMPStock Trend Capital Inc	$ 0.005 (-50.00%)	193.1k
WBIOWPD Pharmaceuticals Inc	$ 0.01 (-50.00%)	119k
AUMCAuric Minerals Corp	$ 1.72 (-43.23%)	566.38k
QIMCQuebec Innovative Materials Corp	$ 0.08 (-11.11%)	2.63M
SOLSOL Global Investments Corp	$ 0.38 (4.11%)	976.71k
NUENU E Power Corp	$ 0.35 (7.69%)	923.5k
IDKThreeD Capital Inc	$ 0.165 (-10.81%)	854.58k
SPODSpod Lithium Corp	$ 0.03 (-14.29%)	822.58k